Claims
- 1. An isolated and purified protein comprising a mammalian K+ channel with two pore domains, wherein said channel produces currents whose current-voltage relationship is weakly inwardly rectifying in high symmetrical K+ conditions.
- 2. The protein of claim 1, wherein said channel is a human K+ channel.
- 3. The protein of claim 1, having a sequence of amino acids as set forth in SEQ ID No. 2.
- 4. A nucleic acid molecule comprising a nucleic acid sequence coding for a mammalian K+ channel with two pore domains, wherein said channel produces currents whose current-voltage relationship is weakly inwardly rectifying in high symmetrical K+ conditions.
- 5. The nucleic acid molecule of claim 4, wherein said molecule is a fragment of said mammalian K+ channel.
- 6. The nucleic acid molecule of claim 4, wherein said K+ channel is a human K+ channel.
- 7. The nucleic acid molecule of claim 4 having an amino acid sequence as set forth in SEQ ID No. 2.
- 8. The nucleic acid molecule fragment of claim 5, wherein said fragment has an amino acid sequence as set forth in SEQ. ID. No. 2, or a part thereof.
- 9. The nucleic acid molecule of claim 6 having an amino acid sequence as set forth in SEQ ID No. 2.
- 10. The nucleic acid molecule of claim 4 comprising SEQ. ID. No. 1.
- 11. The nucleic acid molecule of claim 5 comprising a part of SEQ. ID. No. 1.
- 12. The nucleic acid molecule of claim 6 comprising SEQ. ID. No. 1.
- 13. An antibody directed against a mammalian K+ channel of claim 1.
- 14. The antibody of claim 13, wherein said antibody is a polyclonal antibody.
- 15. The antibody of claim 13, wherein said antibody is a monoclonal antibody.
- 16. The antibody of claim 13, wherein said antibody is a derivative of the antibody directed against said mammalian K+ channel.
- 17. The antibody of claim 13, wherein said antibody is a fragment of the antibody directed against said mammalian K+ channel.
- 18. An integration and expression vector comprising at least one nucleic acid molecule of claim 4, wherein said nucleic acid molecule is operably associated with control sequences.
- 19. A cellular host transformed with the vector of claim 18, which cell expresses a mammalian K+ channel with two pore domains whose current-voltage relationship is weakly inward-rectifying in high symmetrical K+ conditions.
- 20. The transformed cellular host of claim 19, wherein said cellular host is selected from a group consisting of mammalian cells, vertebrate cells and invertebrate cells.
- 21. The transformed cellular host of claim 19, which cells are COS cells.
- 22. A nucleic and oligonucleotide probe prepared from at least one nucleic acid molecule of claim 4 or a part thereof.
- 23. A method for identifying a biologically active compound having anesthetic properties comprising the steps of:
providing a biologically active compound; contacting said compound with a cellular host expressing on its surface a mammalian K+ channel with two pore domains whose current-voltage relationship is weakly inward-rectifying in high symmetrical K+ conditions; determining the K+ transport activity of said mammalian K+ channel; and selecting the compound capable of activating K+ transport as indicative of said compound having anesthetic properties.
- 24. The method of claim 23, wherein said mammalian K+ channel is a human K+ channel.
- 25. The method of claim 23, wherein said mammalian K++channel comprises SEQ. ID No. 2.
- 26. A pharmaceutical composition having anesthetic properties which contains a biologically active compound identified by the method of claim 23.
- 27. The mammalian K+ channel of claim 1, wherein said high symmetrical K+ conditions is a K+-rich external medium of around 150 mM.
CROSS-REFERENCE TO RELATED APPLICATION
[0001] This application is related to U.S. Provisional Application No. 60/214,559, filed on Jun. 27, 2000, and claims the benefit of that earlier filing date. Provisional Application No. 60/214,559 is hereby incorporated by reference in its entirety.
Provisional Applications (1)
|
Number |
Date |
Country |
|
60214559 |
Jun 2000 |
US |